Masayuki Fukata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masayuki Fukata has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Jose Ruiz
Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 1
3 shared publications - Shinichiro Shinzaki
Department of Gastroenterology, Hyogo Medical University School of Medicine, Nishinomiya, Japan
2 shared publications - Taku Kobayashi
Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
2 shared publications - Akihiro Yamada
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Centre , Sakura, Chiba, 285-8741
1 shared publication - Akira Nogami
Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan
1 shared publication Akira Sonoda
Center for Inflammatory Bowel Disease, Department of Internal Medicine, Tokyo Yamate Medical Center, Japan Community Healthcare Organization, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Effectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)
Background: Carotegrast methyl is an oral α4-integrin antagonist used to induce remission in patients with ulcerative colitis with an inadequate response to 5-aminosalicylate (5-ASA). This multicenter, retrospective observational study evaluated the clinical usefulness of carotegrast methyl in real-world practice. Methods: Patients with an inadequate response to 5-ASA who received carotegrast methyl were included. Clinical data were collected during and after treatment for up to 52 weeks. The primary endpoint was the response rate at week 8. The remission rate at week 8, response/remission rate at end of treatment, cumulative response/remission rate, and adverse drug reactions were also assessed. Effectiveness was evaluated using the patient reported outcomes-2 measure (sum of Mayo subscores for stool frequency and rectal bleeding). Results: Data were collected from 196 patients, of whom 180 were evaluable for effectiveness. The PRO-2-defined response and remission rates at week 8 were 57.8% and 43.3%, respectively, and the rates at the end of treatment (median treatment duration: 83.5 days) were 58.9% and 50.0%, respectively. The cumulative PRO-2-defined response/remission rates increased until week 16, followed by a slight further increase. Adverse drug reactions occurred in 31 of 196 patients (15.8%, 43 events), with no serious events. Conclusions: In terms of patient-reported symptom improvement, carotegrast methyl is an effective and well-tolerated treatment for patients with ulcerative colitis who have an inadequate response to 5-ASA. A substantial proportion of patients responded to 8 weeks of treatment. Continued treatment for up to 16 weeks may improve symptoms, even in patients with insufficient response at week 8.
- 28 September 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Open AccessEffectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)
Background: Carotegrast methyl is an oral α4-integrin antagonist used to induce remission in patients with ulcerative colitis with an inadequate response to 5-aminosalicylate (5-ASA). This multicenter, retrospective observational study evaluated the clinical usefulness of carotegrast methyl in real-world practice. Methods: Patients with an inadequate response to 5-ASA who received carotegrast methyl were included. Clinical data were collected during and after treatment for up to 52 weeks. The primary endpoint was the response rate at week 8. The remission rate at week 8, response/remission rate at end of treatment, cumulative response/remission rate, and adverse drug reactions were also assessed. Effectiveness was evaluated using the patient reported outcomes-2 measure (sum of Mayo subscores for stool frequency and rectal bleeding). Results: Data were collected from 196 patients, of whom 180 were evaluable for effectiveness. The PRO-2-defined response and remission rates at week 8 were 57.8% and 43.3%, respectively, and the rates at the end of treatment (median treatment duration: 83.5 days) were 58.9% and 50.0%, respectively. The cumulative PRO-2-defined response/remission rates increased until week 16, followed by a slight further increase. Adverse drug reactions occurred in 31 of 196 patients (15.8%, 43 events), with no serious events. Conclusions: In terms of patient-reported symptom improvement, carotegrast methyl is an effective and well-tolerated treatment for patients with ulcerative colitis who have an inadequate response to 5-ASA. A substantial proportion of patients responded to 8 weeks of treatment. Continued treatment for up to 16 weeks may improve symptoms, even in patients with insufficient response at week 8.
- Open Access
- 9 March 2026
- Published by S. Karger AG in Digestion
- p. 1-11
Involvement of Gastrointestinal Functional Disorder in the Management of Inflammatory Bowel Disease
Background: Recent therapeutic advances have yielded higher remission rates than before in patients with inflammatory bowel disease (IBD), while many patients in remission still experience gastrointestinal symptoms. These persistent symptoms could be caused by functional bowel disorders and are associated with increased psychological distress. Summary: Patients with IBD may have symptoms like functional gastrointestinal disorders (FGID) even before the disease onset, and distinguishing between disease flare and functional symptoms is often difficult. Gastrointestinal infections such as Campylobacter infection may contribute to the onset of both IBD and FGID. The pathophysiology of FGIDs in IBD is complex and multifactorial, involving genetic predisposition, dysregulation of the gut-brain axis, intestinal dysbiosis, impaired mucosal permeability, and low-grade inflammation. These factors further interact with each other to cause symptoms. Key Messages: Management of patients with IBD who present symptoms of FGIDs requires a multifaceted approach based on the principles of FGID treatment under the premise of complete control of intestinal inflammation. In this review, we discuss the clinical overlap, pathophysiology, diagnostic challenges, and a structured approach for patients with IBD who are complicated by symptoms of FGIDs.
- 9 March 2026
- Published by S. Karger AG in Digestion
- p. 1-11
Open AccessInvolvement of Gastrointestinal Functional Disorder in the Management of Inflammatory Bowel Disease
Background: Recent therapeutic advances have yielded higher remission rates than before in patients with inflammatory bowel disease (IBD), while many patients in remission still experience gastrointestinal symptoms. These persistent symptoms could be caused by functional bowel disorders and are associated with increased psychological distress. Summary: Patients with IBD may have symptoms like functional gastrointestinal disorders (FGID) even before the disease onset, and distinguishing between disease flare and functional symptoms is often difficult. Gastrointestinal infections such as Campylobacter infection may contribute to the onset of both IBD and FGID. The pathophysiology of FGIDs in IBD is complex and multifactorial, involving genetic predisposition, dysregulation of the gut-brain axis, intestinal dysbiosis, impaired mucosal permeability, and low-grade inflammation. These factors further interact with each other to cause symptoms. Key Messages: Management of patients with IBD who present symptoms of FGIDs requires a multifaceted approach based on the principles of FGID treatment under the premise of complete control of intestinal inflammation. In this review, we discuss the clinical overlap, pathophysiology, diagnostic challenges, and a structured approach for patients with IBD who are complicated by symptoms of FGIDs.
- Open Access
- 18 February 2026
- Vol. 8 (1) , otag012
Association between serum leucine-rich alpha-2-glycoprotein levels and characteristic enteroclysis findings in small intestinal Crohn’s disease
Enteroclysis provides a whole picture of mucosal and wall-structural information that is advantageous in assessing small intestinal Crohn’s disease (CD). Leucine-rich alpha-2-glycoprotein (LRG) is an acute-phase protein that has been shown to be increased in active CD. We sought to explore the association of LRG with the presence of typical CD findings in enteroclysis. Patients with small intestinal CD whose serum LRG and C-reactive protein (CRP) were measured within 30 days before or after enteroclysis were selected, and were categorized by the presence of longitudinal ulcer, cobblestone appearance, and stricture/narrowing. Levels of LRG were compared by the type and the extent of lesions. Detection performances of LRG and CRP were compared for the presence of each type of lesion. Serum LRG levels were significantly higher in patients who had enteroclysis findings than patients with no findings (23.5 ± 9.2 vs. 12.8 ± 3.0 μg/dL, P < .00001). The level of LRG was not affected by disease extent or history of bowel resection. LRG over 16.3 μg/dL had good detection accuracy for the presence of CD lesions with an area under the receiver operating characteristic curve of 0.85 (95% confidence interval: 0.75-0.95). The association of LRG with the presence of CD-specific lesions was significantly higher than CRP, especially for the presence of stricture/narrowing (AUC: 0.82 vs. 0.67, P = .005) and longitudinal ulcer (AUC: 0.93 vs. 0.80, P = .017). Elevation of serum LRG is associated with the presence of typical CD lesions in the small intestine that may be found in entericlysis.
- 18 February 2026
- Vol. 8 (1) , otag012
Open AccessAssociation between serum leucine-rich alpha-2-glycoprotein levels and characteristic enteroclysis findings in small intestinal Crohn’s disease
Enteroclysis provides a whole picture of mucosal and wall-structural information that is advantageous in assessing small intestinal Crohn’s disease (CD). Leucine-rich alpha-2-glycoprotein (LRG) is an acute-phase protein that has been shown to be increased in active CD. We sought to explore the association of LRG with the presence of typical CD findings in enteroclysis. Patients with small intestinal CD whose serum LRG and C-reactive protein (CRP) were measured within 30 days before or after enteroclysis were selected, and were categorized by the presence of longitudinal ulcer, cobblestone appearance, and stricture/narrowing. Levels of LRG were compared by the type and the extent of lesions. Detection performances of LRG and CRP were compared for the presence of each type of lesion. Serum LRG levels were significantly higher in patients who had enteroclysis findings than patients with no findings (23.5 ± 9.2 vs. 12.8 ± 3.0 μg/dL, P < .00001). The level of LRG was not affected by disease extent or history of bowel resection. LRG over 16.3 μg/dL had good detection accuracy for the presence of CD lesions with an area under the receiver operating characteristic curve of 0.85 (95% confidence interval: 0.75-0.95). The association of LRG with the presence of CD-specific lesions was significantly higher than CRP, especially for the presence of stricture/narrowing (AUC: 0.82 vs. 0.67, P = .005) and longitudinal ulcer (AUC: 0.93 vs. 0.80, P = .017). Elevation of serum LRG is associated with the presence of typical CD lesions in the small intestine that may be found in entericlysis.
- Open Access
- 9 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (12) , 1923-1934
Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study
Background: In randomised controlled trials, mirikizumab achieved clinical remission and improved outcomes of patients with moderate to severe ulcerative colitis (UC). However, there is currently no real‐world evidence for mirikizumab.Aim: To evaluate the real‐world effectiveness and safety of mirikizumab.Methods: In a retrospective cohort study among three facilities, we included patients with UC who first received mirikizumab between June 2023 and April 2024. The primary outcome was the change in the partial Mayo score (PMS) from week 0 to 12. Secondary outcomes included changes in serum C‐reactive protein (CRP) and leucine‐rich α2‐glycoprotein (LRG) levels from week 0 to 12; clinical remission rate (PMS < 2 with rectal bleeding subscore of 0), CRP remission rate (< 3.0 mg/L), and LRG remission rate (< 12.7 μg/mL) at week 12; and adverse events during induction therapy.Results: We included 52 patients. Median (interquartile range) PMS decreased from week 0 to 12 (5 [3–6] to 2 [0–3], p < 0.001). CRP and LRG levels also decreased (CRP: 3.8 [0.9–7.3] to 1.8 [0.5–4.0] mg/L, p = 0.015; LRG: 20.1 [16.3–23.2] to 15.9 [12.8–23.2] μg/mL, p = 0.014). Rates of clinical remission, CRP remission, and LRG remission at week 12 were 44.2%, 67.3%, and 27.3%, respectively. There were no adverse events leading to permanent discontinuation of mirikizumab or death.Conclusion: This real‐world study demonstrated the short‐term effectiveness and safety of mirikizumab in patients with UC.
- 9 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (12) , 1923-1934
Open AccessReal‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study
Background: In randomised controlled trials, mirikizumab achieved clinical remission and improved outcomes of patients with moderate to severe ulcerative colitis (UC). However, there is currently no real‐world evidence for mirikizumab.Aim: To evaluate the real‐world effectiveness and safety of mirikizumab.Methods: In a retrospective cohort study among three facilities, we included patients with UC who first received mirikizumab between June 2023 and April 2024. The primary outcome was the change in the partial Mayo score (PMS) from week 0 to 12. Secondary outcomes included changes in serum C‐reactive protein (CRP) and leucine‐rich α2‐glycoprotein (LRG) levels from week 0 to 12; clinical remission rate (PMS < 2 with rectal bleeding subscore of 0), CRP remission rate (< 3.0 mg/L), and LRG remission rate (< 12.7 μg/mL) at week 12; and adverse events during induction therapy.Results: We included 52 patients. Median (interquartile range) PMS decreased from week 0 to 12 (5 [3–6] to 2 [0–3], p < 0.001). CRP and LRG levels also decreased (CRP: 3.8 [0.9–7.3] to 1.8 [0.5–4.0] mg/L, p = 0.015; LRG: 20.1 [16.3–23.2] to 15.9 [12.8–23.2] μg/mL, p = 0.014). Rates of clinical remission, CRP remission, and LRG remission at week 12 were 44.2%, 67.3%, and 27.3%, respectively. There were no adverse events leading to permanent discontinuation of mirikizumab or death.Conclusion: This real‐world study demonstrated the short‐term effectiveness and safety of mirikizumab in patients with UC.
- Open Access
- 12 January 2016
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 5, 105
Systemic Activation of TLR3-Dependent TRIF Signaling Confers Host Defense against Gram-Negative Bacteria in the Intestine
Recognition of Gram-negative bacteria by toll-like receptor (TLR)4 induces MyD88 and TRIF mediated responses. We have shown that TRIF-dependent responses play an important role in intestinal defense against Gram-negative enteropathogens. In the current study, we examined underlying mechanisms of how systemic TRIF activation enhances intestinal immune defense against Gram-negative bacteria. First we confirmed that the protective effect of poly I:C against enteric infection of mice with Yersinia enterocolitica was dependent on TLR3-mediated TRIF signaling by using TLR3-deficient mice. This protection was unique in TRIF-dependent TLR signaling because systemic stimulation of mice with agonists for TLR2 (Pam3CSK4) or TLR5 (flagellin) did not reduce mortality on Y. enterocolitica infection. Systemic administration of poly I:C mobilized CD11c+, F4/80+, and Gr-1hi cells from lamina propria and activated NK cells in the mesenteric lymph nodes (MLN) within 24 hours. This innate immune cell rearrangement was type I IFN dependent and mediated through upregulation of TLR4 followed by CCR7 expression in these innate immune cells found in the intestinal mucosa. Poly I:C induced IFN-γ expression by NK cells in the MLN, which was mediated through type I IFNs and IL-12p40 from antigen presenting cells and consequent activation of STAT1 and STAT4 in NK cells. This formation of innate immunity significantly contributed to the elimination of bacteria in the MLN. Our results demonstrated an innate immune network in the intestine that can be established by systemic stimulation of TRIF, which provides a strong host defense against Gram-negative pathogens. The mechanism underlying TRIF-mediated protective immunity may be useful to develop novel therapies for enteric bacterial infection.
- 12 January 2016
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 5, 105
Open AccessSystemic Activation of TLR3-Dependent TRIF Signaling Confers Host Defense against Gram-Negative Bacteria in the Intestine
Recognition of Gram-negative bacteria by toll-like receptor (TLR)4 induces MyD88 and TRIF mediated responses. We have shown that TRIF-dependent responses play an important role in intestinal defense against Gram-negative enteropathogens. In the current study, we examined underlying mechanisms of how systemic TRIF activation enhances intestinal immune defense against Gram-negative bacteria. First we confirmed that the protective effect of poly I:C against enteric infection of mice with Yersinia enterocolitica was dependent on TLR3-mediated TRIF signaling by using TLR3-deficient mice. This protection was unique in TRIF-dependent TLR signaling because systemic stimulation of mice with agonists for TLR2 (Pam3CSK4) or TLR5 (flagellin) did not reduce mortality on Y. enterocolitica infection. Systemic administration of poly I:C mobilized CD11c+, F4/80+, and Gr-1hi cells from lamina propria and activated NK cells in the mesenteric lymph nodes (MLN) within 24 hours. This innate immune cell rearrangement was type I IFN dependent and mediated through upregulation of TLR4 followed by CCR7 expression in these innate immune cells found in the intestinal mucosa. Poly I:C induced IFN-γ expression by NK cells in the MLN, which was mediated through type I IFNs and IL-12p40 from antigen presenting cells and consequent activation of STAT1 and STAT4 in NK cells. This formation of innate immunity significantly contributed to the elimination of bacteria in the MLN. Our results demonstrated an innate immune network in the intestine that can be established by systemic stimulation of TRIF, which provides a strong host defense against Gram-negative pathogens. The mechanism underlying TRIF-mediated protective immunity may be useful to develop novel therapies for enteric bacterial infection.
- Open Access
- 20 September 2012
- Published by Taylor & Francis in Gut Microbes
- Vol. 3 (5) , 437-441
TRIF mobilizes unique primary defense against Gram-negative bacteria in intestinal interface
The gastrointestinal tract is the largest mucosal surface in our body. It houses diverse microorganisms that collectively form the commensal microbial community. The security of this community is kept by host-microbial interactions and is violated by foreign pathogens that induce local as well as systemic pathology. In most cases, gastrointestinal infections are caused by Gram-negative enteropathogens, which trigger host immune responses through the TLR4 signaling pathways. Although TRIF is one of the major pathways downstream of TLR4, very little is known about how the TRIF pathway contributes to intestinal defense against pathogenic infection. Recently, we reported a unique role of TRIF signaling in host response to an enterophathogen Yersinia enterocolitica, which consisted of IFN-β induction from regional macrophages followed by activation of NK cells in the mesenteric lymph nodes. In this addendum, we show distinct roles for TRIF-dependent host response in intestinal vs. systemic infection with Gram-negative enterophathogens.
- 20 September 2012
- Published by Taylor & Francis in Gut Microbes
- Vol. 3 (5) , 437-441
Open AccessTRIF mobilizes unique primary defense against Gram-negative bacteria in intestinal interface
The gastrointestinal tract is the largest mucosal surface in our body. It houses diverse microorganisms that collectively form the commensal microbial community. The security of this community is kept by host-microbial interactions and is violated by foreign pathogens that induce local as well as systemic pathology. In most cases, gastrointestinal infections are caused by Gram-negative enteropathogens, which trigger host immune responses through the TLR4 signaling pathways. Although TRIF is one of the major pathways downstream of TLR4, very little is known about how the TRIF pathway contributes to intestinal defense against pathogenic infection. Recently, we reported a unique role of TRIF signaling in host response to an enterophathogen Yersinia enterocolitica, which consisted of IFN-β induction from regional macrophages followed by activation of NK cells in the mesenteric lymph nodes. In this addendum, we show distinct roles for TRIF-dependent host response in intestinal vs. systemic infection with Gram-negative enterophathogens.
- Open Access
- 6 December 2011
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 14 (1) , 15-23
The Role of Innate Immunity in the Host Defense Against Intestinal Bacterial Pathogens
Eradication of infectious disease is our global health challenge. After encountering intestinal infection with a bacterial pathogen, the host defense program is initiated by local antigen-presenting cells (APCs) that eliminate invading pathogens by phagocytosis and establish localized inflammation by secreting cytokines and chemokines. These pathogen-experienced APCs migrate to the mesenteric lymph nodes, where host immune responses are precisely orchestrated. Initiation and regulation of this defense program appear to be largely dependent on innate immunity which is antigen non-specific and provides a rapid defense against broader targets. On the other hand, many bacterial enteropathogens have evoked abilities to modify the host defense program to their advantage. Therefore, better understanding of the host-pathogen interactions is essential to establish effective eradication strategies for enteric infectious diseases. In this review, we will discuss the current understanding of innate immune regulation of the host defense mechanisms against intestinal infection by bacterial pathogens.
- 6 December 2011
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 14 (1) , 15-23
Open AccessThe Role of Innate Immunity in the Host Defense Against Intestinal Bacterial Pathogens
Eradication of infectious disease is our global health challenge. After encountering intestinal infection with a bacterial pathogen, the host defense program is initiated by local antigen-presenting cells (APCs) that eliminate invading pathogens by phagocytosis and establish localized inflammation by secreting cytokines and chemokines. These pathogen-experienced APCs migrate to the mesenteric lymph nodes, where host immune responses are precisely orchestrated. Initiation and regulation of this defense program appear to be largely dependent on innate immunity which is antigen non-specific and provides a rapid defense against broader targets. On the other hand, many bacterial enteropathogens have evoked abilities to modify the host defense program to their advantage. Therefore, better understanding of the host-pathogen interactions is essential to establish effective eradication strategies for enteric infectious diseases. In this review, we will discuss the current understanding of innate immune regulation of the host defense mechanisms against intestinal infection by bacterial pathogens.
- 1 October 2008
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (Supplement) , S90-S92
What are toll-like receptors and what role may they have in IBD?
- 1 October 2008
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (Supplement) , S90-S92
What are toll-like receptors and what role may they have in IBD?